Pacira Biosciences Inc (NASDAQ:PCRX)’s share price shot up 0.6% during trading on Tuesday after SVB Leerink raised their price target on the stock from $45.00 to $58.00. SVB Leerink currently has an outperform rating on the stock. Pacira Biosciences traded as high as $52.49 and last traded at $52.35, 19,931 shares traded hands during mid-day trading. A decline of 97% from the average session volume of 591,986 shares. The stock had previously closed at $52.02.

PCRX has been the topic of a number of other research reports. BidaskClub lowered Pacira Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, May 29th. Piper Sandler reduced their price objective on Pacira Biosciences from $60.00 to $49.00 in a research note on Monday, March 23rd. Guggenheim started coverage on Pacira Biosciences in a research note on Tuesday, May 26th. They issued a “neutral” rating for the company. Northland Securities increased their price objective on Pacira Biosciences from $50.00 to $54.00 and gave the company a “market perform” rating in a research note on Tuesday. Finally, Stifel Nicolaus reduced their price objective on Pacira Biosciences from $49.00 to $48.00 and set a “hold” rating for the company in a research note on Thursday, May 7th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Pacira Biosciences currently has an average rating of “Buy” and a consensus price target of $54.53.

In other news, CEO David M. Stack sold 17,111 shares of Pacira Biosciences stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $48.12, for a total value of $823,381.32. Following the completion of the transaction, the chief executive officer now owns 184,020 shares in the company, valued at approximately $8,855,042.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Lauren Bullaro Riker sold 2,000 shares of Pacira Biosciences stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $42.81, for a total value of $85,620.00. Following the completion of the transaction, the vice president now owns 12,464 shares of the company’s stock, valued at approximately $533,583.84. The disclosure for this sale can be found here. Insiders have sold a total of 43,083 shares of company stock valued at $2,019,772 over the last 90 days. 6.20% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Pacira Biosciences during the 1st quarter worth about $65,000. Victory Capital Management Inc. raised its position in shares of Pacira Biosciences by 23.7% during the 4th quarter. Victory Capital Management Inc. now owns 10,943 shares of the company’s stock worth $473,000 after acquiring an additional 2,098 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Pacira Biosciences by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 335,829 shares of the company’s stock worth $15,214,000 after acquiring an additional 7,801 shares in the last quarter. Comerica Bank acquired a new stake in shares of Pacira Biosciences during the 4th quarter worth about $1,695,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Pacira Biosciences during the 4th quarter worth about $56,000.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 4.63 and a current ratio of 5.37. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -2,569.72, a price-to-earnings-growth ratio of 2.22 and a beta of 1.31. The firm has a 50-day moving average price of $44.53 and a two-hundred day moving average price of $42.09.

Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.30 by $0.23. The company had revenue of $105.68 million for the quarter, compared to analyst estimates of $101.64 million. Pacira Biosciences had a positive return on equity of 13.89% and a negative net margin of 0.02%. The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 earnings per share. Research analysts anticipate that Pacira Biosciences Inc will post 0.95 earnings per share for the current year.

About Pacira Biosciences (NASDAQ:PCRX)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

See Also: Preferred Stock

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.